21 results about "Phosphatidal Compounds" patented technology

The invention discloses a preparation method of composite lipopeptide capable of preventing high-temperature inactivation, and belongs to the technical field of bioactive peptide preparation. The preparation method comprises the following steps: mixing and dissolving a modified phospholipid compound, cholesterol and chloroform, and performing rotary evaporation to obtain a lipid film; mixing and shaking the lipid film, the lipopeptide mixture and a phosphate buffer solution, and performing ultrasonic treatment to obtain a composite lipopeptide liposome suspension; and carrying out spray drying on the composite lipopeptide liposome suspension to obtain composite lipopeptide powder. A lipopeptide mixture obtained through fermentation is mixed with a modified phospholipid compound and cholesterol, a high-temperature-resistant composite lipopeptide liposome suspension is constructed, and after high-temperature spray drying, the obtained composite lipopeptide still has good antibacterial activity.

The invention discloses a phospholipid compound for inhibiting beta-amyloid protein aggregation, and the chemical structural formula of the phospholipid compound is as follows: # imgabs0 #, and n is an integer greater than 2. Dioleoyl phosphatidyl ethanolamine molecules are modified by utilizing maleimide alkyl carboxylic acid and glutathione, so that the interaction between a phospholipid compound and amyloid protein can be effectively regulated and controlled, and the aggregation of the amyloid protein is delayed and even inhibited; the preparation method is simple, the reaction energy consumption is low, and the obtained phospholipid compound has good biocompatibility and is suitable for popularization and application.

The invention belongs to the technical field of pharmaceutical preparations, and particularly relates to an albendazole dispersing agent and a preparation method thereof. The preparation method comprises the following steps: uniformly mixing and dispersing a modified phospholipid compound, a membrane regulator, albendazole and absolute ethyl alcohol, and performing rotary evaporation to obtain the lipid membrane, and adding normal saline into the lipid membrane, mixing and hydrating to obtain the albendazole dispersing agent. Through the technical means of the invention, the albendazole dispersing agent not only has good encapsulation efficiency and storage stability, but also has good in-vitro release performance, and the drug effect can be quickly exerted.

Disclosed in the present application are bis-phosphatidyl amine compounds containing multiple tertiary amino structures, and a composition and the use thereof. The bis-phosphatidyl amine compounds are phospholipid compounds containing two phosphatidyl amine structures, the structures thereof being represented by following formula (I), and the definition of each substituent group being shown in the description. The compounds act together with other lipid components, such as cholesterol, DSPC / DOPE, DMG-PEG2000 and other assistant lipids so as to form lipid nanoparticles (LNPs). The LNPs can be used for high-efficiency delivery of drug molecules such as nucleic acids (siRNA, mRNA and pDNA), thereby achieving diagnosis and treatment of diseases such as cancers, fibrosis (of the liver, lung, kidney, etc.), and editing immune cells.

The present invention relates to a preparation method for and an application of a chiral spirocyclic phosphine-nitrogen-phosphine tridentate ligand SpiroPNP and an iridium catalyst Ir-SpiroPNP thereof. The chiral spirocyclic phosphine-nitrogen-phosphine tridentate ligand is a compound represented by formula I, or a racemate or optical isomer thereof or a catalytically acceptable salt thereof; and the main structural feature is a phosphine ligand having a chiral spiro indene skeleton and a large sterically hindered substituent. The chiral spirocyclic phosphine-nitrogen-phosphine tridentate ligand can be synthesized into a chiral starting material from a 7-diaryl / alkylphosphino-7′-amino-1,1′-spirodihydroindenyl compound having a spiro ring skeleton. The iridium catalyst of the chiral spirocyclic phosphino-7′-amino-1,1′-spirodihydroindenyl compound having a spiro ring skeleton. The iridium catalyst of the chiral spirocyclic phosphine-nitrogen-phosphine tridentate ligand is a compound represented by formula II, or a racemate or optical isomer thereof, or a catalytically acceptable salt thereof. The iridium catalyst can be used to catalyze the asymmetric catalytic hydrogenation of carbonyl compounds, and especially in the asymmetric catalytic hydrogenation of simple dialkyl ketones. Said catalyst exhibits high yield (>99%) and enantioselectivity (up to 99.8% ee), thus having practical value.

The invention provides a D-A type conjugated polymer based on a CDT electron donating unit and a preparation method and application thereof.PCDT-V-DPP is subjected to side chain modification through Y-axis extension of a donor unit, the complete coplanar characteristic is improved, the dihedral angle between a donor and a receptor of the polymer is increased, an absorption peak is expanded to an NIR window region, and the absorption efficiency is improved. Therefore, the photoacoustic imaging signal intensity is improved. The water-soluble nanoparticles PCDT-V-DPP-coated NPs are prepared by taking the PCDT-V-DPP as a core and a phospholipid compound as a shell, and the photoacoustic performance of the water-soluble nanoparticles PCDT-V-DPP-coated NPs is remarkably superior to that of non-Y-axis conjugate extension PCDT-DPP. According to the invention, by carrying out side chain modification on the CDT unit, compared with a non-completely conjugated plane polymer with the same main chain structure, the polymer has higher brightness and signal-to-noise ratio, PCDT-V-DPP has a narrower band gap and a larger dihedral angle, and non-radiation decay can be effectively improved, so that the photoacoustic imaging performance is improved.

Methods of treating tumors by administering compounds to a patient are provided. Compounds such as drugs, may be administered to the patient orally, by injection, intravenously, or topically, which then accumulate as compounds such as a protoporphyrin compound in tumor cells. After such accumulation, such compounds are then activated in various aspects to treat tumors cells, thereby treating cancer. Cancers such as glioblastoma may be treated.

The present disclosure provides phospholipid-containing compounds, pharmaceutical compositions and microspheres that exhibit high affinity for mineralized metals. The present disclosure also provides strategies for using said compounds, compositions and microspheres in the treatment of nephrolithiasis or kidney stone disease, and methods of manufacturing and preparing said compounds and compositions.

The present invention discloses a preparation method of a composite lipopeptide for preventing high-temperature inactivation, belonging to the technical field of bioactive peptide preparation. The preparation method comprises the following steps: a lipid film is obtained by mixing and dissolving a modified phospholipid compound, cholesterol and chloroform and then performing rotary evaporation; after the lipid film, a lipopeptide mixture and a phosphate buffer solution are mixed and shaken, a composite lipopeptide liposome suspension is obtained through ultrasonic treatment; and the composite lipopeptide liposome suspension is spray-dried to obtain a composite lipopeptide powder. In the present invention, the lipopeptide mixture obtained by fermentation is mixed with the modified phospholipid compound and cholesterol to construct a high-temperature-resistant composite lipopeptide liposome suspension, and after high-temperature spray drying, the obtained composite lipopeptide still has good antibacterial activity.

A phosphatidylamine compound including a plurality of tertiary amino group structures and the composition thereof are provided. The phosphatidylamine compound is a phospholipid compound including two or more tertiary amino group structures, the structure of which is represented by the following formula (I). The compound works together with other lipid components such as cholesterol, DSPC / DOPE, DMG-PEG2000, and other helper lipids to form lipid nanoparticles (LNPs), which may be used for efficient delivery of drug molecules such as nucleic acids (siRNA, mRNA, pDNA), thereby realizing diagnosis and treatment of diseases such as cancer, fibrosis (e.g., liver, lung, kidney).

The invention provides a preparation method and application of double-end-group functionalized bionic rubber. The preparation method comprises the following steps: (1) preparing an isoprenyl triblock copolymer from a conjugated monomer containing side group double bonds, isoprene and a hydroxyl isoprene precursor protected by alkyl aluminum under the action of a rare earth catalyst; 2) modifying polar hydroxyl of the copolymer obtained in the step 1) by using a phospholipid compound to obtain single-ended phospholipid functionalized polyisoprene; 3) chemically modifying side group double bonds of the triblock copolymer obtained in the step 2) by using a thiol compound containing amino or / and hydroxyl through thiol-ene click to obtain amino or / and hydroxyl modified phospholipid functionalized polyisoprene; and 4) initiating anhydride ring-opening polymerization by the amino group or / and hydroxyl group introduced in the step 3), and introducing a polypeptide structure into a block at one end of the triblock copolymer to obtain the polypeptide and phospholipid double-end functionalized bionic rubber which has high tensile breaking strength and high 300% stress at definite elongation.

The present invention discloses a selenium phospholipid compound, a synthesis method and a liposome preparation. The structural formula of the selenium phospholipid compound is shown in formula (I): The selenium phospholipid compound of the present invention uses selenium as the core of the antioxidant function, and natural phospholipid molecules serve as the main template, so that it can self-assemble in an aqueous solution to form a liposome structure, greatly improving the water solubility and stability. At the same time, its hydrophilic selenium-containing head is easily exposed on the surface of the liposome, and can quickly contact with the surrounding active oxygen free radicals, thereby achieving a highly efficient antioxidant effect.

The present disclosure provides phospholipid-containing compounds, pharmaceutical compositions and microspheres that exhibit high affinity for mineralized metals. The disclosure also provides strategies for using the compounds, compositions and microspheres in the treatment of renal lithiasis or renal lithiasis, as well as methods of making and making the compounds and compositions.

To provide a method for treating a disease. [Solution] Disclosed are a compound for the treatment of viral infections, a method of using the compound alone or in combination with additional agents, and a pharmaceutical composition of the compound (Formula (I)). Surprisingly, remarkable effects are achieved according to the present invention, as described in detail and demonstrated concretely in this specification, and these remarkable effects could not be easily predicted by those skilled in the art from the prior art. JPEG2026086627000413.jpg40133

Disclosed herein are methods and compositions useful for selectively inhibiting the viability, growth, or metastasis of oral cancer cells, including oral squamous cell carcinomas. Disclosed methods involve contacting such cells with an effective amount of a ceramidase modulator. The ceramidase modulators include at least one phosphorylated dihydroceramide and phospholipid compounds, which can inhibit the viability of the oral cancer cells, for example, by increasing intracellular accumulation of a ceramide and / or a dihydroceramide in the cells or inhibiting the gene expression of ceramidases. Also disclosed are pharmaceutical compositions including ceramidase modulators, such as compositions including phosphorylated dihydroceramide and phospholipid compounds isolated from oral and gut bacteria species, respectively.

The invention provides a D-A type asymmetric non-conjugated polymer based on an ATQ electron withdrawing unit, in which stereo conformation (asymmetric + non-conjugated) PATQ-DPP breaks the planarity of a polymer main chain, and an absorption peak is expanded to an NIR-II window region, so that the photoacoustic signal intensity is effectively improved. The PATQ-DPP is used as a core and is blended with a phospholipid compound through an ultrasonic precipitation method to obtain the water-soluble nano-particles, and the photoacoustic and photothermal properties of the three-dimensional conformation PATQ-DPP-NPs are obviously superior to those of two conjugate plane structures. The ATQ unit is subjected to three-dimensional conformation (asymmetric + non-conjugate) modification, compared with a polymer with a conjugate plane and a main chain structure, the polymer has better brightness and signal-to-noise ratio, PATQ-DPP has a narrower band gap, and therefore the photoacoustic signal intensity is effectively improved, and the photoelectric conversion efficiency is improved. And the nanoparticles prepared by taking the PATQ-DPP as the core for wrapping have higher photothermal conversion efficiency and photoacoustic imaging signals.

To provide a method for controlling morphology of a phospholipid structure and a phospholipid structure, which enable control of liposome association and fission by means of a compound that induces domain formation via self-assembly on a phospholipid membrane, and which are applicable to drug delivery systems or the like through encapsulation of biomolecules.SOLUTION: The present invention provides a method for controlling morphology of a phospholipid structure, comprising: adding a specific amphiphilic compound to a phospholipid aqueous solution comprising two or more phospholipid compounds with different phase transition temperatures so as to form a phospholipid structure; subsequently adding an anionic compound so as to be received by the amphiphilic compound; and thus controlling morphology of the phospholipid structure. The present invention also provides a phospholipid structure obtained by the method.SELECTED DRAWING: Figure 1

A transparent thermoplastic resin composition containing: based on 100 parts by mass of the transparent thermoplastic resin composition, 10 to 60 parts by mass of a graft copolymer (A) obtained by graft copolymerizing a monomer mixture (a) containing at least an aromatic vinyl-based monomer (a1) and a (meth)acrylic acid ester-based monomer (a2) in the presence of a rubbery polymer (R); 40 to 90 parts by mass of a vinyl copolymer (B) obtained by copolymerizing a monomer mixture (b) containing at least an aromatic vinyl-based monomer (b1) and a (meth)acrylic acid ester-based monomer (b2); 100 to 1,000 ppm of a phenolic compound (C); and a dihydrooxaphosphaphenanthrene-based phosphorus compound (D), wherein a molar ratio (P / OH) of a phosphorus atom (P) of the dihydrooxaphosphaphenanthrene-based phosphorus compound (D) to a hydroxyl group (OH) of the phenolic compound (C) is 0.2 to 5.0.